Danaher Corporation (NYSE:DHR) is one of the best strong buy healthcare stocks to buy now. On July 23, UBS lowered the firm’s price target on Danaher Corporation (NYSE:DHR) to $225 from $240, while maintaining a Buy rating on the shares.
A healthcare professional in a lab coat holding a microscope and looking at a slide under the lens.
The firm told investors in a research note that while Danaher Corporation reported Q2 2025 results in line with expectations, its Q3 2025 guidance was slightly below estimates, resulting in a price target downgrade.
Danaher Corporation reported Q2 2025 earnings on July 22, with revenues rising 3.5% year-over-year to $5.9 billion and non-GAAP core revenue increasing 1.5% year-over-year. Net earnings for the quarter reached $555 million, or $0.77 per diluted common share.
For Q3 2025, Danaher Corporation expects non-GAAP core revenue to grow in the low single digits year-over-year.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.
Its Biotechnology segment offers a range of equipment and consumables for biological medicines. In contrast, the Life Diagnostics segment offers clinical instruments, devices, consumables, and other services for diagnosing and treating diseases.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
